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Abstract: A disintegrin andmetalloprotease (ADAM) 17 is a
membrane bound protease, involved in the cleavage and
thus regulation of various membrane proteins, which are
critical during liver injury. Among ADAM17 substrates are
tumor necrosis factor α (TNFα), tumor necrosis factor re-
ceptor 1 and 2 (TNFR1, TNFR2), the epidermal growth factor
receptor (EGFR) ligands amphiregulin (AR) and heparin-
binding-EGF-like growth factor (HB-EGF), the interleukin-6
receptor (IL-6R) and the receptor for a hepatocyte growth
factor (HGF), c-Met. TNFα and its binding receptors can
promote liver injury by inducing apoptosis and necroptosis
in liver cells. Consistently, hepatocyte specific deletion of
ADAM17 resulted in increased liver cell damage following
CD95 stimulation. IL-6 trans-signaling is critical for liver
regeneration and can alleviate liver damage. EGFR ligands
can prevent liver damage and deletion of amphiregulin and
HB-EGF can result in increased hepatocyte death and
reduced proliferation. All of which indicates that ADAM17
has a central role in liver injury and recovery from it.
Furthermore, inactive rhomboid proteins (iRhom) are
involved in the trafficking and maturation of ADAM17 and
have been linked to liver damage. Taken together, ADAM17
can contribute in a complexway to liver damage and injury.
Keywords: ADAM17; IL-6; iRhom; liver damage; regenera-
tion; TNF.
Introduction
Chronic liver disease and liver damage are a major public
health challenge, accounting for more than 1 million deaths
worldwide annually (Byass 2014; Koyama and Brenner
2017). Caused by viral infections, alcoholic and non-
alcoholic liver disease, as well as auto-immune diseases
affecting the liver or bile duct, hepatic inflammation and
injury can result in liver fibrosis, cirrhosis, and even hepa-
tocellular carcinoma (Byass 2014; Iwaisako et al. 2014;
Koyama and Brenner 2017). Tissue damage can cause
further immuneactivation,which can substantially promote
liver inflammation, liver damage, and the development of
pathologic changes such as liver fibrosis (Heymann and
Tacke 2016; Robinson et al. 2016). Several cell death re-
ceptors have been associated with liver damage during liver
disease (Luedde et al. 2014).
A disintegrin and metalloprotease 17 is a membrane
bound protease, which cleaves membrane proteins to
shed them from the plasma membrane (Lambrecht et al.
2018; Zunke andRose-John 2017). Originally, ADAM17was
identified through its role in the proteolytic cleavage of
membrane bound TNFα (Kriegler et al. 1988; Mohler et al.
1994), and named TNFα converting enzyme (TACE) (Black
et al. 1997; Moss et al. 1997). Proteolytic cleavage by
ADAM17 is involved in modulating several important
signaling pathways, which also have been shown to play
an important role in liver regeneration acting as mitogens
for hepatocytes (Berasain et al. 2005a; Kiso et al. 2003;
Michalopoulos 2007; Mitchell et al. 2005; Zarnegar et al.
1991). This review will focus on the role of ADAM17, its
regulation, and ADAM17 dependent pathways during
liver damage.
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ADAM17 protease
ADAM17 is comprised of an N-terminal signal peptide fol-
lowedbyapro-domain, themetalloproteinase domain anda
disintegrin-likedomain, a cysteine-richmembraneproximal
domain (MPD), and a unique Conserved Adam 17 Dynamic
Interaction Sequence (CANDIS) region, succeeded by the
stalk region, transmembrane helix and intracellular cyto-
solic tail (Düsterhöft et al. 2019). ADAM17 and ADAM10,
which is closest to ADAM17 in structure and function, are
atypical members of the ADAM family, as they contain the
MPD region, instead of the cysteine-rich and EGF-like
domain found in other ADAM family proteins (Takeda
2009). The MPD region and the CANDIS, which is not found
in ADAM10, have been reported to be involved in the
dimerization of ADAM17, while the CANDIS region has
further been suggested to facilitate the interaction of
ADAM17 with specific substrates, such as IL-6R (Düsterhöft
et al. 2014; Riethmueller et al. 2016). Notably, in contrast to
ADAM10, ADAM17 is not constitutively active, and multiple
additional mechanisms for how ADAM17 activity is regu-
lated have been brought forward (Grötzinger et al. 2017).
While ADAM17 transcription can be induced by inflam-
mation and in neoplastic tissue, systemic over-expression
was not found to result in upregulated levels of substrate
shedding in vivo (Düsterhöft et al. 2019;Yoda et al. 2013). This
indicated that ADAM17’s proteolytic activity is regulated
at the post-transcriptional level (Armstrong et al. 2006;
Kornfeld et al. 2011; Ringel et al. 2006; Rzymski et al. 2012;
Satoh et al. 2004, 2008). A detailed overview of ADAM17
activity, regulation and substrates is given elsewhere (Zunke
and Rose-John 2017). Briefly, after ADAM17 is synthesized in
the endoplasmic reticulum (ER), it requires various modifi-
cations before it becomes catalytically active. Activation of
ADAM17 ismediated by cleavage of the pro-domain by furin-
like proprotein convertases in the Golgi (Endres et al. 2003;
Schlondorff et al. 2000; Wong et al. 2015) and phosphory-
lation of its cytosolic tail, relieving dimerization inhibition of
ADAM17, via the ERK1/2 and p38 MAPK pathways (Figure 1)
(FanandDerynck 1999; Fan et al. 2003;Gechtmanet al. 1999;
Killock and Ivetic 2010; Lemjabbar-Alaoui et al. 2011; Saad
et al. 2019; Schwarz et al. 2014; Xu and Derynck 2010). In the
ER, the pro-protein is suggested to act as a chaperone for
ADAM17, ensuring correct folding and processing, while
protecting ADAM17 from degradation (Milla et al. 1999). In
addition to this, the pro-protein has been reported to
contribute to active site inhibition of ADAM17. Thus, cleav-
age of thepro-protein is important to release the inhibition of
the catalytic site (Milla et al. 1999). Hence, the processing of
ADAM17 has been suggested to contribute to its activity
following phorbol 12-myristate 13-acetate (PMA) stimulation
(Nagano et al. 2004; Soond et al. 2005). However, the
absence of the cytoplasmic tail is dispensable for PMA
mediated ADAM17 activation (Horiuchi et al. 2007b; Reddy
et al. 2000). Consistently, rapid ADAM17 response following
physiological stimuli requires its transmembrane domain,
but not its cytoplasmic tail (Le Gall et al. 2010).
Additionally, the disintegrin domain has been sug-
gested to play a role in the conformation of the ADAM17
protein, acting as a scaffold ensuring the C-shaped confor-
mation and bridging between the catalytic and the MDP
domain (Takedaet al. 2006). Thismayplaya role in substrate
Figure 1: Schematic representation of the ADAM17 trafficking.
A simplified schematic illustrating that iRhom2 creates a stable complex with ADAM17 in the Endoplasmic Reticulum, which leads to
translocation of the complex to the Golgi apparatus and maturation of ADAM17 by removing the pro-domain by furin-like proprotein
convertases. The mature form consists of a metalloprotease domain and cytosolic tail, which is next phosphorylated by several kinases, like
ERK1/2, p38 MAPK and PLK2. The complex translocates to the cell membrane, where iRhom2 can dissociate from ADAM17.
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binding. Protein disulphide isomerase (PDI) has been
demonstrated to inactivate ADAM17, by changing the
conformation of the MDP region of ADAM17 from an open to
a closed conformation (Düsterhöft et al. 2013, 2014; Lorenzen
et al. 2012). In addition, this has also been suggested to affect
the shedding activity of ADAM17, as only the open form of
MDP binds to phospholipid phosphatidylserines, which are
translocated to the outer leaflet of the cell membrane by
scramblases in response to stimulation with PMA, for
example. This interaction between phospholipid phospha-
tidylserines and open form MDP has been reported to result
in a conformational change, which may contribute to the
initialization of the shedding activity (Sommer et al.
2016a,b). Likewise, the CANDIS region has also been sug-
gested to contribute to the conformational change in
ADAM17 activating its shedding activity. The CANDIS region
has been reported to contain an amphipathic helix, whose
interaction with the cell membrane is enhanced in the
presence of phosphatidylserine. High cholesterol in the cell
membrane, on the other hand, has been found to counteract
this interaction, thus indicating that cell membrane
composition may be involved in the regulation of ADAM17
activity (Düsterhöft et al. 2015; Schütze et al. 2003; Tellier
et al. 2006).
Dimerization of ADAM17 with α5β1 integrin via its dis-
integrin domain has been suggested to promote the binding
of active site tissue inhibitor of metalloproteinase 3 (TIMP3)
(Wisniewska et al. 2008), while decreasing the accessibility
of the active site by steric hindrance (Bax et al. 2004; Huang
et al. 2005). In addition to their role in trafficking ADAM17
from the ER to the Golgi, iRhoms have been demonstrated to
play a role in the regulation of ADAM17 activation at the cell
membrane, with ERK1/2-dependent phosphorylation of the
cytoplasmic iRhom2 resulting in the release of mature
ADAM17and increasedADAM17mediated sheddingofTNFα
(Adrain et al. 2012; Grieve et al. 2017; Maney et al. 2015).
Notably, ADAM17 deficient mice are perinatally lethal,
exhibiting a specific developmental phenotype relating to
epidermal growth factor receptor (EGFR) signaling
(Peschon et al. 1998). These and other signaling pathways
are modulated by ADAM17’s proteolytic activity during
liver damage (Figure 2).
ADAM17 during liver damage
ADAM17 deficient mice are perinatally lethal exhibiting
development defects in the eye, hair and skin, which are
associated with defects in transforming growth factor alpha
(TGFα) shedding (Peschon et al. 1998). However, the
development of a hypomorph mouse model system, in
whichAdam17mRNA and protein levels are highly reduced,
showed a critical role of ADAM17 in intestinal barrier func-
tion while mice were viable (Chalaris et al. 2010). Moreover,
the generation of conditional ADAM17 knockout mice
showed that myeloid specific deletion resulted in the
protection of mice against LPS induced septic shock, with
reduced serum TNFα levels following the challenge
Figure 2: Schematic representation of the ADAM17 enzymatic activities.
A simplified schematic illustrates that ADAM17 can shed substrates from the cell surface, thereby controlling pro-inflammatory and
proliferation pathways. Specifically, TNFα binds to TNFR1, which leads to activation of NF-κB and Jak2/STAT3 pathways respectively, whereas
cleaving the receptors from the cell membrane can result in limited signaling. Other substrates include growth factors like TGFα, heparin-
binding EGF, amphiregulin, and epiregulin, which can bind to EGFR and induce proliferation. Shedding of IL-6R can result in IL-6 trans-
signaling via gp130.
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(Horiuchi et al. 2007a). Both, specific deletion of ADAM17 in
either myeloid cells or hepatocytes resulted in reduced
serum TNFα levels following stimulation with LPS and
partial hepatectomy although liver regeneration appeared
normal in these settings (McMahan et al. 2013). In turn,
hepatocyte specific deletion of ADAM17 resulted in
increased liver cell death following injection with anti-Fas
antibodies, attributed to reduced TNFR1 and EGFR ligand
shedding (Murthy et al. 2010). Consistently, the absence of
TNFR1 reduced CD95 induced apoptosis in this setting
(Murthy et al. 2010). Furthermore, adenoviral mediated
expression of ADAM17 prevented liver cell damage during
acetaminophen induced toxicity (Murthy et al. 2010). In
turn, treatment of mice with α-1 antitrypsin (AAT) showed
increased survival following CD95 stimulation, which
coincided with reduced activity of ADAM17 and decreased
serum levels of TNFα. Consistently, AAT treatment resulted
in protection from liver failure following acetaminophen
induced liver toxicity (Jedicke et al. 2014). These data sug-
gest that there are overlapping functions of ADAM17.
ADAM17 maturation is triggered by co-factors such as
iRhoms, which are inactive members of the rhomboid prote-
ase family (Al-Salihi and Lang 2020). The founding member
rhomboid-1 was identified in Drosophila as a Golgi protein,
which cleaves the EGF like ligand spitz, promoting its secre-
tion (Lee et al. 2001; Urban et al. 2001). However, rhomboid
proteins exist, which lack catalytic residues and are descrip-
tively named inactive rhomboids (iRhom). There are two
iRhom proteins in humans and mice, named iRhom1 and
iRhom2, whereas in Drosophila there is only one iRhom
member (Lemberg and Freeman 2007). IRhoms are unable to
cleave traditional rhomboid substrates and iRhom deficient
flies exhibit an extended sleep cycle, which has been associ-
ated with enhanced EGF receptor signaling (Zettl et al. 2011).
While the single iRhom found in Drosophila induces ER
associated ligand degradation (ERAD) and subsequent inhi-
bition of EGFR signaling, both iRhom1 and iRhom2 have been
shown to interactwithADAM17 (Li et al. 2015; Zettl et al. 2011).
Deletion of both, iRhom1 and iRhom2 resembles the pheno-
type observed in ADAM17 deficient mice (Li et al. 2015).
Moreover, examination of newborn iRhom 1 and 2 double
knockout out mice, demonstrated a significant lack of mature
ADAM17 in multiple tissues examined, including the liver.
Notably, mature ADAM17 expression was also found to be
significantly reduced in livers of iRhom2 knockout mice (Li
et al. 2015). In turn, iRhom1 and iRhom2 single knockoutmice
are viable and fertile (Adrainet al. 2012; Li et al. 2015;McIlwain
et al. 2012; Siggs et al. 2012). These data suggest that iRhom1
and iRhom2 promote ADAM17 maturation in different com-
partments, which allows single knockout mice to overcome
the severe phenotypes observed in ADAM17 deficient mice
(Peschon et al. 1998). In addition to ADAM17 activation,
iRhom proteins may play a role in substrate specificity of
ADAM17 (Maretzky et al. 2013). In mouse embryonic fibro-
blasts (MEF) iRhom2 triggers, among others, shedding of the
EGFR ligands HB-RGF, Amphiregulin, Epiregulin, but not
TGFα (Maretzky et al. 2013). IRhomscanalso regulateADAM17
activation via their cytoplasmic tail. Deletion of the cyto-
plasmic tail results in increased ADAM17 activity and TNFR
shedding, which triggers resistance to TNF mediated cell
death (Maney et al. 2015). The mouse curly bare (cub) muta-
tion,whichdeletesmost of the cytoplasmic domain of iRhom2
showed alterations in EGFR signaling (Hosur et al. 2014; Siggs
et al. 2014). Consistently, iRhom2gainof functionmutations in
its N-terminal cytoplasmic tail, identified in the inherited
Tylosis with oesophageal cancer (TOC) syndrome, result in
increased EGFR ligand and TNFR1 shedding (Blaydon et al.
2012; Brooke et al. 2014; Maney et al. 2015; Saarinen et al.
2012). Dissociation of iRhom2 from ADAM17 takes place after
phosphorylation of the cytoplasmic tail of iRhom2, which can
occur at three different sites. Point mutations in each site
downregulated the activity of ADAM17, while additive muta-
tions resulted in complete loss of ADAM17mediated shedding
(Cavadas et al. 2017; Grieve et al. 2017). Moreover, co-
immunoprecipitation of the extracellular iRhom2 domain in
MEFs upon stimulation with PMA demonstrated reduced
interaction with ADAM17 compared to unstimulated cells.
Grieve et al. concluded that phosphorylation of iRhom2 on the
cell membrane results in the dissociation from ADAM17 fol-
lowed by increased catalytic activity (Grieve et al. 2017).
The regulation of ADAM17 via the interaction with
iRhom2 has been suggested to play a significant role in liver
disease. Absence of iRhom2 resulted in impaired shedding
of TNFα and consequently reduced susceptibility towards
LPSmediated liver damage and septic shock (McIlwain et al.
2012). Moreover, iRhom2 was significantly upregulated
following exposure to a mixture of air pollutants (PM2.5),
which was accompanied by augmented levels of TNFR2,
ADAM17 and TNFα, hepatic steatosis, and dyslipidemia in
the livers of WT mice. Markedly, however, PM2.5-induced
liver damage and dyslipidemia were attenuated in the
absence of iRhom2, while TNFα expression, as well as the
expression of associated pro-inflammatory cytokines, were
reduced in vitro (Ge et al. 2017). Moreover, mature ADAM17
expression and TNFR shedding is increased during bile duct
ligation (BDL), a murine liver fibrosis model system (Sun-
daram et al. 2019). The absence of iRhom2 resulted in
decreased ADAM17 activation and reduced shedding of
TNFRs following BDL. Consequently, hepatic stellate cell
proliferation and liver fibrosis was increased in iRhom2−/−
mice following BDL (Sundaram et al. 2019). Notably,
myeloid and hepatocyte specific deletions of ADAM17 have
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also been associated with decreased TNFα serum levels and
reducedTNFR1 shedding (McMahan et al. 2013;Murthy et al.
2010). Moreover, ursodeoxycholic acid (UDCA), used as a
therapeutic agent for primary biliary cirrhosis and intra-
hepatic cholestasis, has not only been associated with
regulating the expression of inflammatory cytokines,
including TNFα, but has also been demonstrated to improve
BDL-induced cholestasis in mice by inhibiting ADAM17 ac-
tivity and reducing sMet, with a similar trend for TNFα
(Buryova et al. 2013; Ishizaki et al. 2008; Neuman et al.
2002). In addition, iRhom2 is a key regulator of inflamma-
tion driving non-alcoholic fatty liver disease (Xu et al. 2020).
The absence of iRhom2 significantly alleviated insulin
resistance, hepatic steatosis, and activation of inflammatory
macrophages in iRhom2 knockout mice in response to high
fat diet. This was associated with the interaction of hepatic
iRhom2 with mitogen-activated protein kinase 7 (MAP3K7)
and subsequentMAP3K7phosphorylation, leading toNF-κB
signaling and JNK/IRS1 signaling pathway activation, while
impairingAKT/GSK3β-associated insulin signaling (Xu et al.
2020). Similarly, hepatocyte specificdeletion ofADAM17has
been shown to improve liver steatosis in a mouse model of
NAFLD/NASH (Casagrande et al. 2017). Taken together,
ADAM17 dependent signaling is critical during liver damage
and in liver disease (Table 1).
ADAM17-dependent pathways and
their role during liver damage
TNFα signaling
TNFα is a central cytokine during liver damage (Koyama and
Brenner 2017; Luedde et al. 2014). Named for its anti-tumor
activity, it was originally identified in the late ’70s and is the
Table : Overview of the ADAM dependent pathways on liver disease.
Liver diseases Examples for relevant ADAM-regulated processes Reference studies
Liver fibrosis and cirrhosis TNFα was associated with mediating NF-κB induced HSC
activation, as well as promoting HSC survival, thereby
contributing to liver fibrosis indirectly.
(Osawa et al. ; Pradere et al.
; Tarrats et al. )
Cleavage of MerTK, contributed to the activation of HSCs
and promoted liver fibrosis in NASH.
(Cai et al. )
Amphiregulin induced fibrogenic activity of hepatic stel-
late cells and promoted liver fibrosis.
(Berasain et al. b; McKee et al.
; Santamaria et al. )
Hepatocellular carcinoma TNF signaling via NF-κB was reported to have a protective,
anti-apoptotic effect, which contributes to hepatocyte
carcinogenesis.
(Schwabe and Brenner )
EGFR activation was shown to have a tumor-promoting role. (Fuchs et al.; Lanayaet al.)
Hepatic ADAM regulation by TIMP slowed
tumorgenesis.
(Casagrande et al. )
Alcoholic and non-alcoholic fatty liver dis-
ease (NAFLD) as well as non-alcoholic
steatohepatitis (NASH)
Augmented levels of EGFR ligand amphiregulin was
induced by fibrogenic activity of hepatic stellate cells,
driving liver fibrosis.
(McKee et al. )
ADAM-mediated cleavage of MerTK was demonstrated
to contribute to the activation of HSCs, driving liver fibrosis
in NASH.
(Cai et al. )
iRhom overexpressing mice showed inflammatory
aggravation mediated by NF-κB activation, whereas in the
ADAM KO model, mice had alleviated hepatic steatosis.
(Casagrande et al. ; Xu et al.
)
Viral hepatitis TNFα was shown to be crucial to mounting an appropriate
T-cell response to infection with hepatitis B virus.
(Beyer et al. ; Kasahara et al.
)
TNFα was associated with increased cell death via sup-
pression of NF-κB during viral infection.
(Park et al. ; Xu et al. )
Liver regeneration HGF and EGFR ligands, HB-EGF and amphiregulin acted as
mitogens for hepatocytes during liver regeneration.
(Berasain et al. a,b; Kiso et al.
; Mitchell et al. ; Takemura
et al. )
IL- was shown to have a transignaling role in liver
regeneration.
(Fazel Modares et al. ; Jin et al.
; Riethmueller et al. )
IL-was shown to have a role inmaintaining the biliary tree
in liver.
(Demetris et al. ; Nozaki et al.
)
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founding member of a superfamily of cytokine-like mole-
cules (Carswell et al. 1975; Green S Fau-Chiasson et al.).
Along with their cognate receptors, the TNFR superfamily
control signaling pathways in immunity and disease (Dos-
tert et al. 2019; Kondylis and Pasparakis 2019). TNFα can
induce signaling via two cognate receptors TNFR1 and
TNFR2. TNFα has been shown to promote liver damage
during toxic liver damage (Yin et al. 1999). Injection of TNFα
can cause severe liver damage and septic shock when
applied in combination with D-Galactosamine (D-Gal),
which is dependent on TNFR1 (Luedde et al. 2014). Consis-
tently, TNFR1 deficient mice are protected from liver injury
and septic shock following lipopolysaccharide (LPS) chal-
lenge (Pfeffer et al. 1993; Rothe et al. 1993). TNFR1 is ubiq-
uitously expressed and can be activated by both shed and
membrane bound TNFα. TNFR2 on the other hand is
expressed in a more limited fashion on immune, neuronal,
cardiac, endothelial and stem cells and binds membrane
bound TNFα with higher affinity (Dostert et al. 2019).
Notably, ADAM17 can cleavemembraneboundTNFα into its
soluble form as well as the binding receptors TNFR1 and
TNFR2 (Peschon et al. 1998). Accordingly, ADAM17 con-
tributes to soluble TNFα’s systemic effects. Conversely,
shedding of the TNFRs reduces TNFR1 signaling, and
resulting soluble TNFRs can bind to TNFα thereby reducing
its biological activity. Therefore, depending on the balance
of TNFα versus TNFR cleavage and the predominant cell on
which this happens, ADAM17 can have opposite effects on
liver damage and fibrosis. Furthermore, the TNF pathway
once activated also has dual outcomes when it comes to
hepatocyte death and proliferation.
The binding of TNFα to TNFR1 results in a conforma-
tional change exposing the death domain of TNFR1. This
leads to the recruitment of the adaptor protein TNFR1-
associated death domain (TRADD) via the interaction of the
death domains. The interaction of TNFR1 and TRADD
provides an assembly scaffold for the recruitment of further
adaptormolecules, resulting in the formation of complexes
I and II and subsequent induction of TNF signaling. Com-
plex I consists primarily of the receptor itself, the adaptor
protein TRADD, TNFR-associated factor 2 (TRAF-2), cellular
inhibitors of apoptosis 1 and 2 (cIAP1/2), linear ubiquitin
chain assembly complex (LUBAC) and receptor-interacting
serine/threonine-protein kinase 1 (RIPK1). Complex II is
comprised of three distinct, Fas-associated death domain
(FADD) and long isoform of FLICE-like inhibitory protein
(FLIPL) containing sub complexes, IIa-c. Phosphorylation,
ubiquitination and de-ubiquitination of RIPK1 controls
whether TNFα binding to TNFR1 results in signaling via
complex I or complex II (Feoktistova et al. 2011; Wang et al.
2008; Yu and Cleveland 2018). The TNFα-TNFR1 signaling
pathway can induce several different cellular responses
including inflammation, apoptosis and necrosis by acti-
vating gene transcription in downstream signaling path-
ways such as NF-κB, JNK, and p38.
Complex I activates downstream NF-κB signaling
resulting in the expression of pro-inflammatory and pro-
survival genes (Dostert et al. 2019; Hsu et al. 1995, 1996;
Kondylis and Pasparakis 2019; Ting et al. 1996). In turn, NF-
κB inhibition and complex II formation results in cell death
and induces tumor regression (Dostert et al. 2019; Fulda
2015; Kondylis and Pasparakis 2019; Xie et al. 2016). The
mode of cell death induced depends on which type of com-
plex II is formed and the presence or absence of active cas-
pase 8. In complex II FLIPL mirrors caspase 8 and is
catalytically inactive, but forms catalytically active hetero-
dimers, which have a reduced activity and altered targets
compared to caspase 8 homodimers (Dostert et al. 2019; Pop
et al. 2011). While the short isoforms (S and R) bind to cas-
pase 8 and inhibit its activation (Golks et al. 2005; Irmler
et al. 1997). Complexes IIa and IIb induce apoptosis, are
caspase 8 dependent and contain either TRADD or RIPK1
respectively. Absence of active caspase 8 results in nec-
roptosis (Holler et al. 2000; Vercammen et al. 1998; Zhang
et al. 2009). Caspase 8 is an initiator caspase; when active, it
triggers a downstream cascade of caspase cleavage, leading
to activation of effector caspases such as caspase 3, ulti-
mately leading to apoptosis (Dostert et al. 2019; Stennicke
et al. 1998). Consistently, TNFα expression levels correlate
with active caspase 3 in patient cohorts suffering from hep-
atitis C virus infection, which can increase the sensitivity
towards TNFα mediated cell death (Park et al. 2012; Walsh
et al. 2004). TNFα promotes chronic viral infection and
hepatitis inmurineviral infectionmodel systems (Beyer et al.
2016; Suresh et al. 2005; Xu et al. 2014; Zhuang et al. 2020),
and Hepatitis B virus infection sensitizes hepatocytes to-
wards TNFαmediated cell death (Jia et al. 2015). In contrast
to Complexes IIa and IIb, Complex IIc, also known as the
necrosome, depends on RIPK1, 3 and mixed lineage kinase
domain-like (MLKL) to induce necroptosis via the insertion
of MLKL into the plasmamembrane creating an ion channel
(Cai et al. 2014; Dostert et al. 2019; Galluzzi et al. 2014;
Kondylis and Pasparakis 2019; Wang et al. 2008, 2014;
Weber et al. 2018). Notably, complex II formation can occur
independently of its role in cell death and inflammation. This
last has been linked to chromosomal stability, suggesting a
possible mechanism relating loss of caspase 8 to hepato-
cellular carcinoma (HCC) among other cancers (Liccardi
et al. 2019; Soung et al. 2005).
During liver fibrosis, TNFα produced by Kupffer cells
and neutrophils induces Hepatic stellate cell (HSC) acti-
vation and proliferation. Specifically, TNFα and LPS
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promote proliferation and survival of HSCs by activating
NF-κB and down-regulating pro-apoptotic genes (Gandhi
2017; Osawa et al. 2013; Seki et al. 2007). Accordingly,
liver damage and fibrosis were decreased in TNFR1 KO
mice and TNFR1&2 double knockout mice compared to
wild-type or single TNFR2 KO mice in a murine model
system of fibrosis, suggesting TNF-TNFR1 but not TNFR2
is critical for HSC activation and liver fibrosis (Tarrats
et al. 2011).
IL-6 receptor signaling
IL-6 signaling is induced by IL-6, secreted during the in-
flammatory response, binding to its non-signal transducing
α-receptor IL-6R and the signaling receptor gp130 (Tanaka
et al. 2014). IL-6 signaling can also be induced in cells
lacking membrane bound IL-6R, albeit IL-6 cannot bind to
gp130 in the absence of IL-6R. However, IL-6 cannot bind to
gp130 on its own, but rather gp130 binds the IL-6/IL-6R
complex (Schmidt-Arras andRose-John 2016). This signaling
requires the shedding of membrane bound IL-6R. Active
ADAM17 and ADAM10 can cleave IL-6R, resulting in soluble
IL-6R (sIL-6R) (Müllberg et al. 1993; Riethmueller et al. 2017).
Accordingly, sIL-6R can still bind IL-6 and gp130 on cells,
which lack IL-6R, and induce gp130 mediated signaling, so-
called IL-6 trans-signaling (Mackiewicz et al. 1992). IL-6
expression during the inflammatory response to injury, re-
sults in the induction of acute phase proteins such as
C-reactive protein and fibrinogen. In the liver, IL-6,
expressed by neutrophils, monocytes andmacrophages, is a
major force driving the expression of acute phase proteins
(Schmidt-Arras and Rose-John 2016). Aside from its role
prominent as a potent pro-inflammatory cytokine, IL-6 has
been reported to play a critical role in liver regeneration.
Hepatectomy in rats results in increased TNFα levels, suc-
ceeded by significantly increased IL-6 expression (Trautwein
et al. 1996). Consistently, B cells and macrophages triggered
IL-6 expression in mice following partial hepatectomy
(Behnke et al. 2018). In the absence of IL-6 signaling tissue
regeneration after partial hepatectomy was impaired
(Cressman et al. 1996; Fazel Modares et al. 2019). Likewise,
inhibition of IL-6 signaling resulted in increased liver dam-
age in response to carbon tetrachloride (CCL4) induced liver
damage (Gewiese-Rabsch et al. 2010). Moreover, liver injury
was exacerbated by inhibition of IL-6 signaling in a non-
alcoholic steatohepatitis (NASH) model (Yamaguchi et al.
2011). The absence of gp130 – abolishing all IL-6-type cyto-
kine signaling– resulted in increased liver damage following
BDL, which was associated with increased bacterial burden
(Wuestefeld et al. 2005). Moreover, lack of IL-6, gp130, and
STAT3 signaling in the liver promoted establishment of
steatohepatitis (Kroy et al. 2010).
While classical signaling via the membrane-bound IL-6
receptors is associated with the inflammatory role of IL-6,
IL-6 trans-signaling has been suggested to play a major role
in liver regeneration. Hyper-IL-6 is a fusion protein between
IL-6 and soluble IL-6R, which stimulates trans-signaling in
gp130 expressing cells (Schmidt-Arras and Rose-John 2016).
Mice expressing Hyper-IL-6 exhibited hepatocellular hy-
pertrophy and accelerated liver regeneration following
partial hepatectomy (Peters et al. 2000). Consistently, in a
mouse model exhibiting only IL-6 trans-signaling, liver
regeneration following partial hepatectomy was compara-
ble to control animals (Fazel Modares et al. 2019). Further-
more, administration of Hyper-IL-6 during toxic liver injury
could alleviate liver damage and promote hepatocyte pro-
liferation (Galun et al. 2000). Taken together, these findings
suggest a prominent role of IL-6 trans-signaling, triggered
by ADAM17 IL-6R cleavage, during liver regeneration.
Reduced IL6-trans-signaling might result in increased liver
damage and prolonged injury.
EGFR signaling
ADAM17 can cleave a variety of EGFR ligands including
amphiregulin, heparin-binding-EGF-like growth factor, epi-
regulin, TGFα and epigene (Sahin and Blobel 2007; Sahin
et al. 2004; Sigismund et al. 2018). Conditional deletion of
EGFR on hepatocytes was associated with increased liver
transaminases and reduced survival following partial hep-
atectomy (Natarajan et al. 2007). Consistently, mice with
hepaticdeletionofEGFRshowed increased liver damageand
cancer formation following DEN treatment (Lanaya et al.
2014). In turn, macrophage specific deletion of EGFR caused
reduced cancer growth (Lanaya et al. 2014). Treatment with
the EGFR inhibitor erlotimib alleviated the establishment of
liver fibrosis and the development of hepatocellular carci-
noma (Fuchs et al. 2014). In turn, ectodomain shedding of
EGFR ligands and TNFR1 can critically regulate acute liver
damage (Murthy et al. 2010). Conditional deletion of HB-EGF
results in increased liver injury following acute toxic hepa-
titis (Takemura et al. 2013). Furthermore, overexpression of
HB-EGF results in aggravated liver fibrosis following chronic
liver injury (Guo et al. 2017). Deletion of amphiregulin pre-
vented hepatocyte proliferation following partial hepatec-
tomy. Furthermore, pretreatment with amphiregulin could
prevent liver damage following CD95 stimulation (Berasain
et al. 2005b). Consistently, amphiregulin deficient mice
showed increased liver injury during bile duct ligation
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(Santamaria et al. 2019). Collectively, these reports hint to a
rather protective role of EGFR ligands and thus a potentially
prominent role for ADAM17 shedding during liver injury but
cell, substrate, and context specific effects might apply.
Other substrates
Likewise, the receptor for hepatocyte growth factor, c-Met
has been reported to play a significant role in liver devel-
opment and regeneration (Chalupský et al. 2013). Chalupský
et al. demonstrate that ADAM17 along with ADAM10 are
involved in releasing the soluble form of the c-Met receptor,
sMet from the cell surface in human hepatocellular HepG2
and hepatic stellate cell LX2 lines, while postulating a
dominant role for ADAM17. Moreover, serum levels of sMET
in a hepatobiliary obstruction mouse model correlated with
the level of hepatic injury, expression of establishedmarkers
of liver damage including alanine aminotransferase (ALT),
aspartate transaminase (AST), alkaline phosphatase (ALP),
and total bilirubin, as well as with subsequent regeneration
(Chalupský et al. 2013). Hepatocyte specific, post partum
deletion of c-Met resulted in increased hepatocyte apoptosis
and reduced proliferation following transfer experiments
(Kaldenbach et al. 2012). Consistently, hepatocyte specific
deletion of c-Met resulted in fulminant liver damage and
lower hepatocyte proliferation following bile duct ligation
(BDL) (Giebeler et al. 2009).
ADAM17 as a therapeutic target
Since its discovery as a protease involved in the activation of
the TNF pathway, ADAM17 has been a focal point of research
aiming to find new therapeutics for inflammatory diseases
(Calligaris et al. 2021). However, due to its involvement in the
regulation of multiple signaling pathways, with over 80
different substrates aside from TNF reported, and the simi-
larity of its catalytic domain to ADAM10, which plays an
important role in vascularisation, cell proliferation and dif-
ferentiation, and several other metalloproteinases, targeting
ADAM17 has proven difficult (Calligaris et al. 2021; Maskos
et al. 1998; Riethmueller et al. 2016; Wetzel et al. 2017; Zunke
and Rose-John 2017). Initial drugs designed to target ADAM17
activity demonstrated severe side effects, including serious
hepatotoxicity, outweighing their therapeutic benefits (Calli-
garis et al. 2021; Moss et al. 2008; Rossello et al. 2016). Thus,
the risk of deregulating numerous physiologically relevant
processes and the broad expression of ADAM17 throughout
the body, pose a caveat for targeting ADAM17 therapeutically
(Calligaris et al. 2021; Zunke and Rose-John 2017).
Nevertheless, several promising approaches have been
explored recently andare reviewed inmoredetail byCalligaris
et al. (2021). These include the use of more specific small
molecules, manipulating the selectivity of endogenous in-
hibitors of ADAM17, aswell as targeting the ancillary domains
of ADAM17 or regulators, that are specific and essential for
ADAM17 activation, such as iRhoms (Calligaris et al. 2021). For
example, Wong et al. developed a stable form of the auto-
inhibitorypro-domainofADAM17 (orTACEpro-domain), TPD,
which demonstrated promising attenuation of ADAM17-
mediated disease in models of sepsis, rheumatoid arthritis
(RA) and inflammatory bowel disease aswell as inRApatients
(Wong et al. 2016).
Notably, targeting iRhom2 therapeutically is a particu-
larlypromising route:Not only is iRhom2specific forADAM17,
but also it carries the advantage that, iRhom1 can substitute
for the loss of iRhom2-mediated regulation of ADAM17. At the
same time, using iRhom2 as a therapeutic target could regu-
late several pro-inflammatory ADAM17-mediated factors,
including IL-6 signaling (Calligaris et al. 2021).
Concluding remarks
ADAM17 substrates play a critical role during liver damage
in various model systems. Furthermore, data from condi-
tional ADAM17 deficient mice corroborate the significance
of ADAM17 during liver damage. Myeloid deletion of
ADAM17 resulted in reduced soluble TNFα production. In
turn, hepatocyte specific deletion resulted in increased
liver damage resulting from reduced shedding of TNFRs.
Furthermore, IL-6 trans-signaling is important for liver
regeneration and hepatocyte proliferation. Accordingly,
cell type specific regulation of ADAM17 is critical to
orchestrating liver regeneration and liver damage. In
addition, adaptor molecules such as iRhoms might cause
cell specific or substrate specific ADAM17 activity and thus
could critically regulate liver damage during diseasemodel
systems. However, further characterization of ADAM17 in
different cell subsets is required to fully understand the
complete picture of ADAM17 during liver damage and
disease. This is particularly important to further explore
ADAM17 or its regulators as a therapeutic target.
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